Saturday, March 20, 12:54 am IST
Hot Searches:  inflationcementBharti
| Feedback
Moneycontrol » News Center » Business » Business News

Want more about Business to land in your mailbox?

Set an alert here

India, EU to resolve generic drug dispute: Trade min

Published on Mon, Nov 09, 2009 at 12:59   |  Updated at Mon, Nov 09, 2009 at 13:04  |  Source : Reuters
Google Buzz

India will resolve a dispute with the European Union over generic drugs in an amicable way, Trade Minister Anand Sharma said on Friday.

A formal trade dispute has loomed between India and Brazil on one side, and the EU on the other. The case threatened to escalate to India and Brazil taking the EU to court at the World Trade Organisation.

Developing countries believe the case, originally involving the seizure by Dutch customs of a blood pressure drug en route from India to Brazil last December, is a symbol of their mistreatment by rich nations and corporations.

"They have taken tangible steps," Sharma told reporters after talks with EU officials in the Indian capital. "We both are committed to resolve the outstanding matter amicably."

Sharma said the shipment of drugs was consistent with WTO regulations.

The row sums up a major dilemma in trade and intellectual property policy — how to reconcile the provision of affordable medicine to people in poor countries with the need to encourage medical research through patent protection.

Sharma was joined at a press conference by the EU Trade Commissioner Catherine Ashton, who said officials on both sides were meeting later in November to resolve the dispute.

"We have no intention to stop the legitimate export or transit of generic medicine," Ashton said. "We want to work together to resolve the issue."

What's your Opinion

CEO Wall See All

Martin Pieters

Martin Pieters

MD and CEO

Vodafone

See major growth opportunities in rural India: Vodafone

Rakesh Parikh

Rakesh Parikh

VP-Finance

Unichem Lab

Domestic formulations to grow significantly ahead: Unichem

Koshi Varghese

Koshi Varghese

Executive VP-Marketing

MRF

Input costs hitting margins, see tyre price hike ahead: MRF

Venkat Jasti

Venkat Jasti

Chief Executive Officer

Suven Life Sciences

See 25% growth in CRAMS biz next year: Suven Life Sciences

WHAT OTHERS LIKE
  • Most Read
  • Most Viewed
24 Hours
7 Days
1 Month
NEWS FROM OUR PARTNERS
©Network 18, 2010. All Rights Reserved